Home » Exelixis Announces Cometriq Is Now Available in the U.S.
Exelixis Announces Cometriq Is Now Available in the U.S.
Exelixis announced the commercial availability of Cometriq (cabozantinib) for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Businesswire
Businesswire
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May